The endothelin axis in cancer: The promise and the challenges of molecularly targeted therapy

Anna Bagnato, Francesca Spinella, Laura Rosanò

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The endothelin (ET) axis, which includes ET-1, ET-2, ET-3, and 2 G protein-coupled receptor subtypes, ETAR and ETBR, promotes growth and progression of a variety of tumors, such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, lung, bladder, endometrial carcinoma, Kaposi's sarcoma, brain tumors, and melanoma. Acting on selective receptors, ET-1 regulates mitogenesis, cell survival, angiogenesis, bone remodeling, stimulation of nociceptors, tumor-infiltrating immune cells, epithelial-to-mesenchymal transition, invasion, and metastatic dissemination. At the molecular level, endothelin receptor antagonists, besides providing ideal tools for dissecting the ET axis, have demonstrated their potential in developing novel therapeutic strategies. Emerging experimental and clinical data demonstrate that interfering with endothelin receptors provides an opportunity for the development of rational combinatorial approaches using endothelin receptor antagonists in combination with chemotherapy or molecularly targeted therapy.

Original languageEnglish
Pages (from-to)473-484
Number of pages12
JournalCanadian Journal of Physiology and Pharmacology
Volume86
Issue number8
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Endothelin-2
Endothelins
Endothelin-3
Endothelin A Receptors
Endothelin Receptors
Lung
Nociceptors
Epithelial-Mesenchymal Transition
Bone Remodeling
Kaposi's Sarcoma
Endothelin-1
Endometrial Neoplasms
G-Protein-Coupled Receptors
Combination Drug Therapy
Brain Neoplasms
Melanoma
Neoplasms
Cell Survival
Urinary Bladder
Breast

Keywords

  • Antitumor therapy
  • Endothelin
  • Endothelin receptor antagonist
  • G protein-coupled receptor

ASJC Scopus subject areas

  • Physiology
  • Pharmacology

Cite this

The endothelin axis in cancer : The promise and the challenges of molecularly targeted therapy. / Bagnato, Anna; Spinella, Francesca; Rosanò, Laura.

In: Canadian Journal of Physiology and Pharmacology, Vol. 86, No. 8, 08.2008, p. 473-484.

Research output: Contribution to journalArticle

@article{19849cb0b65f420ca9391c23f77d820c,
title = "The endothelin axis in cancer: The promise and the challenges of molecularly targeted therapy",
abstract = "The endothelin (ET) axis, which includes ET-1, ET-2, ET-3, and 2 G protein-coupled receptor subtypes, ETAR and ETBR, promotes growth and progression of a variety of tumors, such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, lung, bladder, endometrial carcinoma, Kaposi's sarcoma, brain tumors, and melanoma. Acting on selective receptors, ET-1 regulates mitogenesis, cell survival, angiogenesis, bone remodeling, stimulation of nociceptors, tumor-infiltrating immune cells, epithelial-to-mesenchymal transition, invasion, and metastatic dissemination. At the molecular level, endothelin receptor antagonists, besides providing ideal tools for dissecting the ET axis, have demonstrated their potential in developing novel therapeutic strategies. Emerging experimental and clinical data demonstrate that interfering with endothelin receptors provides an opportunity for the development of rational combinatorial approaches using endothelin receptor antagonists in combination with chemotherapy or molecularly targeted therapy.",
keywords = "Antitumor therapy, Endothelin, Endothelin receptor antagonist, G protein-coupled receptor",
author = "Anna Bagnato and Francesca Spinella and Laura Rosan{\`o}",
year = "2008",
month = "8",
doi = "10.1139/Y08-058",
language = "English",
volume = "86",
pages = "473--484",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "8",

}

TY - JOUR

T1 - The endothelin axis in cancer

T2 - The promise and the challenges of molecularly targeted therapy

AU - Bagnato, Anna

AU - Spinella, Francesca

AU - Rosanò, Laura

PY - 2008/8

Y1 - 2008/8

N2 - The endothelin (ET) axis, which includes ET-1, ET-2, ET-3, and 2 G protein-coupled receptor subtypes, ETAR and ETBR, promotes growth and progression of a variety of tumors, such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, lung, bladder, endometrial carcinoma, Kaposi's sarcoma, brain tumors, and melanoma. Acting on selective receptors, ET-1 regulates mitogenesis, cell survival, angiogenesis, bone remodeling, stimulation of nociceptors, tumor-infiltrating immune cells, epithelial-to-mesenchymal transition, invasion, and metastatic dissemination. At the molecular level, endothelin receptor antagonists, besides providing ideal tools for dissecting the ET axis, have demonstrated their potential in developing novel therapeutic strategies. Emerging experimental and clinical data demonstrate that interfering with endothelin receptors provides an opportunity for the development of rational combinatorial approaches using endothelin receptor antagonists in combination with chemotherapy or molecularly targeted therapy.

AB - The endothelin (ET) axis, which includes ET-1, ET-2, ET-3, and 2 G protein-coupled receptor subtypes, ETAR and ETBR, promotes growth and progression of a variety of tumors, such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, lung, bladder, endometrial carcinoma, Kaposi's sarcoma, brain tumors, and melanoma. Acting on selective receptors, ET-1 regulates mitogenesis, cell survival, angiogenesis, bone remodeling, stimulation of nociceptors, tumor-infiltrating immune cells, epithelial-to-mesenchymal transition, invasion, and metastatic dissemination. At the molecular level, endothelin receptor antagonists, besides providing ideal tools for dissecting the ET axis, have demonstrated their potential in developing novel therapeutic strategies. Emerging experimental and clinical data demonstrate that interfering with endothelin receptors provides an opportunity for the development of rational combinatorial approaches using endothelin receptor antagonists in combination with chemotherapy or molecularly targeted therapy.

KW - Antitumor therapy

KW - Endothelin

KW - Endothelin receptor antagonist

KW - G protein-coupled receptor

UR - http://www.scopus.com/inward/record.url?scp=48849097102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849097102&partnerID=8YFLogxK

U2 - 10.1139/Y08-058

DO - 10.1139/Y08-058

M3 - Article

C2 - 18758494

AN - SCOPUS:48849097102

VL - 86

SP - 473

EP - 484

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 8

ER -